Background: There is a growing interest in the potential of mesenchymal stem cells
INTRODUCTION
Mesenchymal stromal cells (also known as mesenchymal stem cells; MSC) are regarded as multipotent progenitors 1 with the ability to modulate inflammatory responses 2 and migrate to injury sites 3 . They can likely be derived from almost all tissues, and should express certain cell surface markers, such as CD105, CD73 and CD90 and be negative for hematopoietic cell surface markers (as reviewed in 4 ). Finally, they must be able to differentiate into osteoblasts, chondroblasts and adipoblasts 5 .
There is a growing interest in the therapeutic potential of MSC; thus, administration of MSC in different animal models was found to have restorative effects in liver fibrosis 6 , myocardial infarction 7 and Alzheimer's disease (AD) 8 . There is also evidence that with age, the pool of MSC becomes progressively smaller and the remaining cells lose vitality, a fact that led one of us (EM) to hypothesize that there is an age-related stem cell exhaustion syndrome which may be responsible for a number a chronic pathologies, including aging itself 9 . Here, we report that long-term intravenous administration of human bone marrow-derived MSC in a single female rat was associated with a remarkably long survival, 44 months, as compared with an average lifespan of 36 months for most albino rats.
MATERIAL AND METHODS

Animals
Sprague-Dawley rats are raised in our rat colony at INIBIOLP. They are housed in a temperature-controlled room (22 ± 2º C) on a 14:10 h light/dark cycle. Food and water are available ad libitum. In our rat colony, the average 50% survival time for females, studied in groups of 50-60 animals, is approximately 32 months, provided mammary tumors are systematically removed when detected by palpation. The rat under treatment This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
belonged to a group of 50 virgin females to be used in the future when they were between 27-29 months old. The rat was placed alone in a standard stainless steel square cage. Typically, our female rats show an almost flat survival curve (100 % alive) until age 24-26 months when they begin to die in progressively increasing numbers. All experiments with animals were performed in accordance to the Animal Welfare This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
CD45, CD34, CD14, CD11b, CD79, CD19 and HLA-DR surface molecules expression, microbiologically tested and caryotyped to confirm they were normal. The MSC were then placed in low glucose DMEM with 20% FBS and 10% DMSO and cryopreserved in liquid nitrogen. This preparation was the source of MSC for the whole study. For each injection, a cell aliquot was thawed and cultured, with regular examination under a phase-contrast inverted microscope. Finally, the MSC were detached, concentrated by centrifugation, their concentration properly adjusted and delivered to the rat as described below.
Treatment with MSC
A suspension of MSC in low glucose DMEM (5x10 6 cells in 0.5 ml) was injected with a tuberculin syringe fitted to a 25G needle, in one of the tail veins. The treatment was started at 6 months of age and the MSC injections were administered every two weeks until the end of the study.
RESULTS
The MSC injections did not cause any observable changes in the rat, either beneficial or detrimental. As the animal aged it progressively developed bilateral cataracts which became severe after 30 months of age. This pathology was also observed in the majority of the intact counterparts. Although there is a high incidence of nonmetastatic mammary tumors in our aging females (which are surgically removed shortly after detection in order to prolong the animals' life) none was detected in the treated rat. The body weight of the experimental rat showed a slight increase as it aged. It was 291g at 27 months, This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
anestrus. At 42 months of age the treated rat showed a mobility and exploratory activity roughly comparable to that of 26-month-old intact counterparts when placed on the Barnes maze. At this age the rat showed no paralysis or dragging of the hind legs and displayed a normal posture (Fig. 1) . 
DISCUSSION
The average lifespan of laboratory rats is 3 years 10 and up to now, calorie restriction remains as the only proven intervention able to substantially extend lifespan in rodents. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
female Sprague-Dawley rats it was shown that 50% food restriction induces a severe panhypopituitarism as well as an arrest in ovulation and estrous cyclicity. Upon refeedeing, the rats resumed estrous cycles and remained cycling for longer than their full-fed counterparts 12 .
Unlike calorie restricted rats, the MSC treated rat gained weight at the same rate as the Another study suggests that the plasma from young mice contains molecules able to improve cognitive functions in old mice 17 . Taken together, the above studies are consistent with the hypothesis of a stem cell exhaustion syndrome as a relevant (although not exclusive) cause of aging and chronic pathologies 9 . The heterologous MSC used in the present study came from a patient approaching old age, yet the treated rat had a lifespan 22% longer than the avearge lifespan of laboratory rats. Since this is, to our knowledge, the first report of a life extending activity of MSC in rats, it would be premature to postulate a mechanism for this effect. Clearly, the tolerance of the rat to these heterologous MSC was very high. Importantly, preliminary experiments in which we intracerebroventricularly administered human MSC to 27-month old female rats or streptozotocin-lesioned young males (an AD model) revealed only a mild restorative effect on spatial memory. This suggests that MSC therapy must be started during adulthood or youth in order to significantly extend life and delay the onset of agerelated pathologies. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Concluding remarks
This is a 4.5-year long experiment with a design weakness that stems from the minimal N value used, a limitation that is at least partly counterbalanced by the high unlikelihood of finding by chance such a long-lived individual in our rat colony.
Clearly, the results are not conclusive but they invite further exploration. We believe that the potential rewards of confirming the present findings warrant investing the time and resources needed to replicate the study with a higher N value. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
